What we know about the femininity of the future





menopause, examination, Femininity of the Future


The level of awareness about the problems of maintaining health and the quality of life in menopause is an extremely important issue not only among women of the appropriate age, but also among doctors of various specialties. Founded on the initiative of the specialists of the State Institution “E.M. Lukyanova Institute

of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, the social and information project “Femininity of the Future” is aimed specifically at assessing the health status, awareness and frequency of the examination of women aged 40+; drawing attention to the need for regular examination and application of modern medical devices and technologies, identification of a group of high cardiovascular risk and the risk of development of oncological pathology, compiling relevant registers, increasing the level of knowledge among physicians of various specialties on modern approaches to the prevention, diagnosis and treatment of climacteric disorders.

The obtained intermediate results of the program make it possible to introduce practical recommendations for raising awareness and reducing risks among women, and to optimize the training of doctors, which is what the population needs at this time. The continuation of the social and information project

“Femininity of the Future” in 2018–2020 provides us with more opportunities to conduct a broad educational program to preserve the quality of life, the social activity of women in the post-productive period and methods for reducing the risks of developing cardiovascular and oncological pathologies among: doctors of related specialties, women of pre-menopausal age; women who are already in the menopause period (without manifestations of the climacteric syndrome and in its presence); to develop fundamental new technologies both in medicine and in other spheres of public life. The creation of an online version of the project in 2018 will ensure a qualitatively new level of its implementation.

Author Biographies

Ю. Г. Антипкін, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”

MD, professor, academician of the NAMS of Ukraine, director

Т. Ф. Татарчук, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”

MD, professor, corresponding member of the NAMS of Ukraine, deputy director for research work, сhief of the Endocrine Gynecology Department

О. О. Єфименко, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”

PhD, senior researcher at the Endocrine Gynecology Department


  1. “National consensus on the management of patients in menopause.” Reproductive endocrinology 1.27 (2016): 8–25.
  2. Boardman, H.M.P, et al.“Hormone therapy for preventing cardiovascular disease in post-menopausal women.” The Cochrane Database of Systematic Reviews 3 (2015): CD002229.
  3. Burcu Ceylan. “Factors affecting age of onset of menopause and determination of quality of life in menopause.” Turk J Obstet Gynecol 12.1 (2015): 43–9.
  4. Dreisler, E., Poulsen, L.G., Antonsen, S.L., et al. “EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal women.” Maturitas 75.2 (2013): 181–90.
  5. Franco, O.H., Chowdhury, R., Troup, J., et al. “Use of Plant-Based Therapies and Menopausal Symptoms.” JAMA 315.23 (2016): 2554–63.
  6. Dąbrowska, J., Dąbrowska-Galas, M., Naworska, B., et al. “The role of physical activity in preventing obesity in midlife women.” Prz Menopauzalny 14.1 (2015: 13–19.
  7. Kirk-Sanchez, N., McGough, E. “Physical exercise and cognitive performance in the elderly: current perspectives.” Clin Interv Aging 9 (2014): 51–62.
  8. Lethaby, A., Marjoribanks, J., Kronenberg, F., et al. “Phytoestrogens for menopausal vasomotor symptoms.” Cochrane Database of Systematic Reviews 12 (2013): CD001395.
  9. Marjoribanks, J., Farquhar, C., Roberts, H., et al. “Long-term hormone therapy for perimenopausal and postmenopausal women.” The Cochrane Database of Systematic Reviews 1 (2017): CD004143.
  10. Puciato, D., et al. “Quality of life and physical activity in an older working-age population.” Clin Interv Aging 2017; 12: 1627–1634.
  11. Schneider, H.P.G., Naftolin, F. Climacteric medicine: where do we go? London. Taylor & Francis (2005): 28.
  12. The North American Menopause Society. “The 2017 hormone therapy position statement of The North American Menopause Society.” Menopause 24.7 (2017): 728–53.
  13. Gerhard, I., Ventskovsky, B. “Klimaktoplant H in patients with acute menopausal complaints.” ISRCTN registry ID ISRCTN16340124 (2017). Available from: [http://www.isrctn.com/ISRCTN16340124].
  14. Resolution of the Expert council on the implementation of the social-information project. “Maintaining the quality of life and social activity of women in the postreproductive period.” Reproductive endocrinology 4.36 (2017): 9–12.



How to Cite

Антипкін, Ю. Г., Татарчук, Т. Ф., & Єфименко, О. О. (2018). What we know about the femininity of the future. REPRODUCTIVE ENDOCRINOLOGY, (40), 10–14. https://doi.org/10.18370/2309-4117.2018.40.10-14



Health care

Most read articles by the same author(s)

1 2 3 4 > >>